Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00402779 · ClinicalTrials.gov registry record · Phase 3
Erlotinib Prevention of Oral Cancer (EPOC)
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 303
- Enrollment target
NCT00402779: Completed Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00402779 is a Phase 3 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 303 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00402779, a Phase 3 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 303 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if erlotinib hydrochloride (Tarcevaâ (OSI-774 ) can prevent cancer in the mouth of people with a high risk of developing cancer in the mouth. The safety of this drug will also be studied, as well as the drug's effect on different cells in the body.
Interventions
- DRUG Placebo
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 303 participants |
| Start Date | 2006-11-03 |
| Est. Completion | 2018-06-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00402779
The ClinicalTrials.gov registry entry for NCT00402779 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 303 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00402779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00402779 about?
NCT00402779 is a clinical study titled "Erlotinib Prevention of Oral Cancer (EPOC)". The goal of this clinical research study is to learn if erlotinib hydrochloride (Tarcevaâ (OSI-774 ) can prevent cancer in the mouth of people with a high risk of developing cancer in the mouth. The safety of this drug will also be studied, as well as the drug's effect on different cells in the body...
What is the current status of trial NCT00402779?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 303 participants. The study started on 2006-11-03. Estimated completion is 2018-06-04.
What interventions are being tested in trial NCT00402779?
The interventions under investigation include: Placebo (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00402779?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.